{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382825895623761671.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Jason Auer"}],"foaf:familyName":[{"@value":"Auer"}],"foaf:givenName":[{"@value":"Jason"}]}],"career":[{"institution":{"notation":[{"@value":"BIND Biosciences Inc., Cambridge, MA 02139, USA."}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825895623761664","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1126/scitranslmed.3003651"},{"@type":"URI","@value":"https://www.science.org/doi/pdf/10.1126/scitranslmed.3003651"}],"notation":[{"@value":"Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1126/scitranslmed.3003651_5Vesde9Kw3wFkL0RQwF07AKcENE"}]}